
The Trump administration abruptly halted a Pittsburgh Alzheimer's study in its fifth and final year, wasting more than $8 million in taxpayer money and leaving Black participants in the city's Hill and Homewood neighbourhoods without the answers they had spent years helping scientists find, according to an Associated Press report published on Sunday, November 22, 2026. The study had spent 15 years building trust in communities where Black Americans face twice the risk of developing the disease as their white peers.
People in Pittsburgh's historically Black Hill and Homewood communities took memory tests, tracked their sleep and blood pressure, and shared stories of their past to help scientists unravel why Black Americans are twice as likely as their white peers to develop Alzheimer's disease. The study was near completion in its fifth and final year when the National Institutes of Health stripped its funding, on the grounds that it was "not science", despite rigorous review and vetting from a community advisory board. The cut was part of a wider hunt for medical grants whose descriptions contain the words "disparities", "minority" and "racial", the AP report says. A separate study by Ann Cohen, a director of Pittsburgh's Alzheimer's Disease Research Center, was also halted after spending $5.2 million over three years, and she has joined the same lawsuit.
The Pittsburgh Alzheimer's study was never only about data. Trust in American health institutions has long been strained in the Black community, rooted in racial health inequities and unequal access to care. The legacy of the Tuskegee study, which withheld treatment from Black men with syphilis in the 1930s, still casts a shadow. The Pittsburgh study overcame that mistrust, one conversation at a time. Getting people involved in Hill and Homewood got people talking about memory loss and dementia, said La'Vette Wagner, the study's field coordinator. The stakes were high: 55% of Black Americans believe that a significant loss of memory is a natural part of ageing rather than a disease, according to the Alzheimer's Association. As participant Roderick Blair, 70, put it: "You start forgetting things and you start to wonder, do you have Alzheimer's? You wonder, do you have dementia?"
What made the study unusual was how deeply it was rooted in the neighbourhoods it studied. Participants were part of a research relationship built over years, with a community advisory board vetting the work. Wagner was blunt about what the cut did to that relationship. "It wasn't a Black study or a DEI study," she said. "It was something that was happening that was real." Blair, who took part for four years, described how the halt will look from inside the community: "The community will look like, 'Oh, they came in here, they took all our stuff, they checked us out. Now they're gonna leave us hanging.'" Cohen put the damage in a single line: "You lose trust a hell of a lot faster than you build it."
The administration defended the decisions. A spokesperson for the Department of Health and Human Services said: "Massive amounts of DEI grants have failed to translate into better health outcomes for minority populations. Following President Trump's directives, NIH is shifting money into rigorous research that will help Americans — including minority populations — live longer, healthier lives." The scientists affected tell a different story. Negar Fani, a neuropsychologist at Emory University, was two years into a five-year, $2.9 million project on how racial discrimination affects the brain and body of Black Americans when the NIH terminated it in July. Fani is now trying to find the roughly $2.3 million needed to finish. "It takes a lot to restore trust with the Black community, who has experienced so many different betrayals," she said. "It's simply brain science research." Jill Rosenthal, of the Center for American Progress, said: "We're wasting resources, we're wasting the opportunity to identify cures for diseases."
The Pittsburgh case is not an isolated cut. This year, the NIH has awarded 2,000 fewer grants for multiyear studies, worth $200 million, compared with 2025, according to an Association of American Medical Colleges report. Each terminated grant strands participants and data, and erodes communities' willingness to take part in the next study. Black Americans develop Alzheimer's at twice the rate of white Americans, yet the research that might explain why is the research being cut. The findings that do exist are, as Wagner said, "stuck on a shelf". And the human cost falls on people like Blair, who may never learn what his own tests showed.
The fight is now in court. Lead researcher Andrea Rosso is one of numerous scientists in a recently filed lawsuit against the NIH and its parent department, and Ann Cohen has joined the same action. The lawsuit will test whether grants that passed rigorous peer review can be terminated on the grounds that they are "not science". Fani is searching for the roughly $2.3 million she needs to finish her study. Whether the funding is restored or not, the trust that took 15 years to build will take far longer to repair.
What was the Pittsburgh Alzheimer's study? A research project in Pittsburgh's Hill and Homewood communities studying why Black Americans are twice as likely as white peers to develop Alzheimer's disease.
Why was the study halted? The National Institutes of Health stripped its funding in its fifth and final year on the grounds that it was "not science", despite rigorous review and vetting from a community advisory board.
How much money was wasted? Researchers say more than $8 million had already been spent. A separate study by Ann Cohen was halted after spending $5.2 million over three years.
What happens to the participants now? They will not learn what their brain tests showed, and researchers say the findings are "stuck on a shelf".
Is the funding cut being challenged? Yes. Lead researcher Andrea Rosso is among scientists suing the NIH and the Department of Health and Human Services, and Ann Cohen has joined the same lawsuit.
Related coverage: Flu hospital admissions jump 22% as early H1N1 season hits highest rate since 2010; US measles cases surge past 7,700 as 13 deaths reported in 2026; California voters approve Proposition 38, an $8.4 billion medical research bond.